Brief: Lineage Cell Therapeutics Says Opc1 Cell Therapy For The Treatment Of Spinal Cord Injury To Return To Clinical Testing

Lineage Cell Therapeutics

22/06/2021 11:51

June 22 (Reuters) - Lineage Cell Therapeutics Inc  LCTX.A :
    * LINEAGE’S OPC1 CELL THERAPY FOR THE TREATMENT OF SPINAL
CORD
INJURY TO RETURN TO CLINICAL TESTING
    * LINEAGE CELL THERAPEUTICS INC - SAFETY STUDY ELIGIBILITY
IS
EXPECTED TO INCLUDE PATIENTS WITH CHRONIC INJURY
    * LINEAGE CELL THERAPEUTICS INC - LATE-STAGE CLINICAL STUDY
CONTINUES TO BE PLANNED FOR 2022
    * LINEAGE CELL THERAPEUTICS INC - RMAT INTERACTION WITH FDA
HELD
TO PROPOSE CLINICAL TESTING OF A NOVEL DELIVERY DEVICE FOR OPC1
    * LINEAGE CELL THERAPEUTICS INC - INTENDS TO SUBMIT AN
AMENDMENT
TO ITS IND APPLICATION FOR OPC1 TO SUPPORT A PHASE 1 CLINICAL
STUDY

Source text for Eikon:  ID:nBwbmg53Ka 
Further company coverage:  LCTX.A 

 ((reuters.briefs@thomsonreuters.com;))